EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) have been assigned an average recommendation of “Buy” from the five analysts that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have updated their coverage on […]
More Stories
StockNews.com Initiates Coverage on China Pharma (NYSE:CPHI)
StockNews.com assumed coverage on shares of China Pharma (NYSE:CPHI – Free Report) in a report published on Thursday. The firm...
Athersys (NASDAQ:ATHX) Coverage Initiated at StockNews.com
StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX – Free Report) in a research note published on Thursday. The firm...
RLI (NYSE:RLI) Shares Scheduled to Split on Thursday, January 16th
Shares of RLI Corp. (NYSE:RLI – Free Report) are set to split on Thursday, January 16th. The 2-1 split was...
Martin Marietta Materials (NYSE:MLM) Rating Increased to Hold at StockNews.com
StockNews.com upgraded shares of Martin Marietta Materials (NYSE:MLM – Free Report) from a sell rating to a hold rating in...
Landmark Bancorp (NASDAQ:LARK) Now Covered by Analysts at StockNews.com
StockNews.com started coverage on shares of Landmark Bancorp (NASDAQ:LARK – Free Report) in a research note released on Thursday. The...
Tripadvisor (NASDAQ:TRIP) Downgraded by StockNews.com to Hold
StockNews.com cut shares of Tripadvisor (NASDAQ:TRIP – Free Report) from a buy rating to a hold rating in a research...